Effective treatment of advanced biliary tract carcinoma using 5- fluorouracil continuous infusion with cisplatin

Annals of Oncology

Volumn 9, Issue 6, 1998, Pages 653-656

  Ducreux, M ^a   Rougier, P ^a   Fandi, A ^a   Clavero Fabri, M C ^a   Villing, A L ^a   Fassone, F ^a   Fandi, L ^a   Zarba, J ^a   Armand, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biliary tract cancer; Chemotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LEUKOPENIA; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CARCINOMA; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031871963     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008241008379     Document Type: Article

References (14)

1. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54: 965 9.
2. Taal BG, Audisio RA, Bleiberg H et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study. Ann Oncol 1993; 4: 607 9.
3. Harvey JH, Smith FP, Schein PS. 5-fluorouracil. mitomycin and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2: 1245 8.
4. Okada S, Ishii H, Nose H et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994; 51: 515 7.
5. Rougier P, Zarba JJ, Ducreux M et al. Phase II study of cisplatin and 120-hour infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993; 4: 333 6.
6. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 201 14.
7. Rougier P, Fandi A, Ducreux M et al. Demonstrated efficiency of 5-fluorouracil continuous infusion and cisplatin in patients with advanced biliary tract carcinoma. Proc Am Soc Clin Oncol 1995; 14: 205 (Abstr).
8. Jones DVJ, Lozano R, Hoque A et al. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 14 (8): 2306 10.
9. Takada T, Kato H, Matsushiro T et al. Comparison of 5-fluorouracil. doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51: 396-400.
10. Kajanti M, Pyrhönen S. Epirubicin-sequential methotrexate 5-fluorouracil leucovorin treatment in advanced cancer of the extrahepatic biliary system: A phase II study. Am J Clin Oncol 1994; 17: 223-6.
11. Patt YZ, Jones DVJ, Hoque A et al. Phase II trial of intravenous fluorouracil and subcutaneous interferon-α-2b for biliary tract cancer. J Clin Oncol 1996; 14 (8): 2311 5.
12. Ellis PA, Hill NA, O'Brien MER et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995; 31A (10): 1594-8.
13. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced oesophago-gastric cancer. J Clin Oncol 1997; 15: 261 7.
14. Glimelius B, Hoffman K, Sjöden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593 600.